Guselkumab is also an IL-23 inhibitor, and a case of an ACH patient with single finger involvement whose rash continued to worsen after ixekizumab treatment was reported to have disappeared after switching to guselkumab microinjection therapy. This evidence concerns the gene IL23A and achondroplasia.